DexCom CGM System to Offer Real-Time Glucose Data Sharing

DexCom CGM System to Offer Real-Time Glucose Data Sharing

DexCom G4® Platinum Continuous Glucose Monitoring System with Share Allows Users to Wirelessly Transmit Blood-Glucose Data and Alerts to Up to Five “Followers” in Real-Time    Medical device manufacturer DexCom is rolling out the first FDA-approved continuous glucose monitoring (CGM) system that allows real-time sharing of blood-glucose data. The DexCom G4® Platinum Glucose Monitoring System with […]

Investigating the Role of Regulatory T Cells in T1D

A video explains a potential new immune therapy in the words of the T1D investigator and one of the clinical study participants JDRF Research in the Field spoke to the lead investigator, Dr. Stephen Gitelman at the University of California San Francisco’s Children’s Hospital, who enrolled 14 people recently diagnosed with Type 1 Diabetes (T1D) […]

Next-Generation Artificial Pancreas System Launches

Medtronic’s New MiniMed®640G Artificial Pancreas System Predicts and Helps Prevent Deadly Low Glucose Emergencies A four year-old Australian boy with type 1 diabetes (T1D) is the first person to use a groundbreaking commercial artificial pancreas system that can predict and automatically prevent low blood-glucose emergencies. Medtronic’s MiniMed® 640G is an insulin pump/continuous glucose monitor combination […]

T1D Trial Looks to Teach an Old Drug New Tricks

JDRF-funded clinical study of a drug called TUDCA looks to improve beta cell functioning in people recently diagnosed with T1D Until recently, much of type 1 diabetes (T1D) research has focused on suppressing the autoimmune system to prevent or reverse disease, but this approach has been slow to yield promising, long-term results in people with […]

Re-educating the Immune System in T1D

JDRF partner Selecta developed a novel technology for creating a T1D vaccine to potentially halt the disease process It has been more than 30 years since scientists identified the basic autoimmune feature of type 1 diabetes (T1D) when they discovered autoantibodies binding to targets from cells in the pancreas. And yet, devising therapies to halt […]

Unlocking a Combination Therapy for New Onset T1D

A new study is further assessing if a novel combination of drugs could help treat new onset type 1 diabetes University of Florida researchers are ready to launch a new clinical study to examine if a combination of two U.S Food and Drug Administration (FDA) approved drugs, antithymocyte globulin (ATG) and granulocyte colony stimulating factor […]

Advancing a Key Artificial Pancreas Technology

Stable liquid glucagon developed by JDRF partner Xeris evaluated in first clinical study The JDRF Artificial Pancreas (AP) project is focused on accelerating the development of commercially-viable AP systems that better mimic the biological function of the pancreas and reduce the daily burden of managing type 1 diabetes (T1D). To achieve this goal, JDRF funds […]

Improving Beta Cell Health and Survival

JDRF-funded clinical study to test marketed drug to improve beta cell health and survival in T1D JDRF recently awarded a $2.1 million grant to Anath Shalev, M.D., director of the University of Alabama’s (UAB) Comprehensive Diabetes Center, to test the impact of a common blood pressure drug called verapamil on the health and survival of […]

Historic Progress for JDRF Encapsulation Research Program

First people with type 1 diabetes receive experimental encapsulated cell replacement therapies in clinical studies Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are evaluating two distinct encapsulation therapies. Encapsulated cell replacement therapy involves […]